Drugs in Development
All Data
Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE
Lead Product(s): CoronaVac
Therapeutic Area: Infections and Infectious Diseases Product Name: CoronaVac
Highest Development Status: Approved Product Type: Vaccine
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable September 22, 2020
Details:
The phase III clinical trial seeks to test efficacy and safety of CoronaVac in Turkey and aims to be a pivotal study to support the licensure of this product.
Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE
Lead Product(s): CoronaVac
Therapeutic Area: Infections and Infectious Diseases Product Name: CoronaVac
Highest Development Status: Approved Product Type: Vaccine
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable September 09, 2020
Details:
Phase 3 clinical trials of a potential COVID-19 vaccine developed by China’s Sinovac Biotech Ltd have shown promising results and it may be available to Brazilians as early as December.
Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE
Lead Product(s): Lianhua Qingwen
Therapeutic Area: Infections and Infectious Diseases Product Name: KT07
Highest Development Status: Approved Product Type: Undisclosed
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable September 05, 2020
Details:
Lianhua Qingwen Capsules was approved to be registered as a drug to treat symptoms like fever, cough, debilitation, sore muscles, nasal obstruction, runny nose, headaches, a dry and sore throat, shortness of breath, and a red tongue caused by viral diseases including COVID-19.
Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE
Lead Product(s): CoronaVac
Therapeutic Area: Infections and Infectious Diseases Product Name: CoronaVac
Highest Development Status: Approved Product Type: Vaccine
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable August 28, 2020
Details:
Sinovac Biotech Ltd’s coronavirus vaccine candidate CoronaVac was approved for emergency use as part of a programme in China to vaccinate high-risk groups such as medical staff.
Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE
Lead Product(s): Quadrivalent Influenza vaccine
Therapeutic Area: Infections and Infectious Diseases Product Name: QIV
Highest Development Status: Approved Product Type: Vaccine
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable June 24, 2020
Details:
QIV contains two A strains and two B strains, recommended by the WHO, and the vaccine protects a target group of 3 years and older against the influenza disease.
Market Place
Active Pharmaceutical Ingredients
Finished Drug Formulations
Price
Excipients
Services
Marketplace
